Part I. Advances in heart transplantation

Disease-a-Month

Volumn 45, Issue 3, 1999, Pages 62-87

  Winkel, Elaine ^a,b,c,d   Disesa, Verdi J ^b,e,f,g   Costanzo, Maria Rosa ^{a,b,d,h,i,j,k,l}  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h Section of Cardiology

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j Malpighi Hospital   (Italy)

^k UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^l ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADRENALIN; ALCOHOL; ANTIBIOTIC AGENT; ATROPINE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN A; DIGITALIS; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDRALAZINE; IMMUNOSUPPRESSIVE AGENT; ISOPRENALINE; KETOCONAZOLE; LYMPHOBLAST ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; PHENYTOIN; QUINIDINE; TACROLIMUS; THYMOCYTE ANTIBODY; TUBERCULOSTATIC AGENT; VERAPAMIL;

BONE MARROW SUPPRESSION; COMORBIDITY; CONJUNCTIVITIS; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HLA MATCHING; HUMAN; HYPERTENSION; LYMPHOPROLIFERATIVE DISEASE; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; OBESITY; OBSTRUCTIVE JAUNDICE; PANCREATITIS; PERSONALITY DISORDER; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PROGNOSIS; REVIEW; CONGESTIVE HEART FAILURE; FOLLOW UP; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; SURVIVAL RATE;

FOLLOW-UP STUDIES; GRAFT REJECTION; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE;

EID: 0033087791     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-5029(99)90013-5     Document Type: Review

References (58)

1. Hosenpud JD, Bennett LE, Berkeley MK, Fiol B, Boucek MM, Novick RJ. Registry of the International Society for Heart and Lung Transplantation: fifteenth official report-1998. J Heart Lung Transplant 1998;17:656-68.
2. Benenson E, editor. United network for organ sharing bulletin. Richmond (VA): UNOS; 1989.
3. Benensen E, editor. United network for organ sharing bulletin. Richmond (VA): UNOS; 1998.
4. UNOS (Richmond, VA) and the Division of Transplantation, Office of Special Programs, Health Resources and Services Administration, US Department of Health and Human Services (Rockville, MD). 1997 annual report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network-transplant data: 1988-1996. Richmond (VA): UNOS; 1997.
5. Stevenson LW, Hamilton MA, Tillisch IH, et al. Decreasing survival benefit from cardiac transplantation for outpatients as the waiting list lengthens. J Am Coll Cardiol 1991;18:919-25.
6. Baumgartner WA, Reitz BA, Oyer PE, et al. Cardiac homotransplantation. Curr Probl Surg 1979;16:1-61.
7. Cohn JN, Archibald DG, Ziesche A, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veteran's Cooperative Study. N Engl J Med 1986;314:1547-52.
8. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol 1987;59:634-8.
9. Gradman A, Deedwania P, Cody R, et al for the Captopril-Digoxin Study Group. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol 1989;14:564-70.
10. Anguita M, Arizon JM, Bueno G, et al. Clinical and hemodynamic predictors of survival in patients aged less than 65 years with severe congestive heart failure secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1993;72:413-7.
11. Campana C, Gavazzi A, Berzuini C, et al. Predictors of prognosis in patients awaiting heart transplantation. J Heart Lung Transplant 1993;12:756-65.
12. Dec GW, Fifer MA, Hermann HC, Cocca-Spoffbrd D, Semigran MJ. Long-term outcome of enoximone therapy in patients with refractory heart failure. Am Heart J 1993;125(Pt 1):423-9.
13. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993;87(Suppl 6):VI-17-23.
14. Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-52.
15. Bittner V, Weiner DH, Yusef S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 1993; 270:1702-7.
16. Szlachcic J, Massie BM, Kramer BL, Topic N, Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol 1985;55:1037-42.
17. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
18. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 1984;311:819-23.
19. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
20. Luu M, Stevenson LW, Brunken RC, Drinkwater DC, Schelbert HR, Tillisch JH. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80:1675-80.
21. Zado ES, Gottlieb CD, Marchlinski FE, Butscher DM, Paugh EJ, Jessup M. Exacerbation of heart failure precedes sudden death in patients with and without implantable defibrillators. J Heart Lung Transplant 1994;13:S50.
22. Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 1992;85(Suppl I):I-50-6.
23. Costanzo MR, Augustine S, Bourge RC, et al. Selection and treatment of candidates for heart transplantation: a statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995;92:3593-3612.
24. Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multi institutional study. J Heart Lung Transplant 1993;12:549-62.
25. Pierce GA, Graham WK, Kauffman HM Jr, Wolf JS. The United Network for Organ Sharing:1984-1994. Transplant Proc 1996;28:12-5.
26. Blanche C, Valenza M, Czer LSC, et al. Combined heart and kidney transplantation with allografts from the same donor. Ann Thorac Surg 1994;58:1135-8.
27. Soifer BE, Gelb AW. The multiple organ donor: identification and management. Ann Intern Med 1989;110:814-23.
28. Darby JM, Stein K, Grevnik A, Stuart SA. Approach and management of the heart beating "brain dead" organ donor. JAMA 1989;261:2222-8.
29. Emery RW, Cork RC, Levinson MM, et al. The cardiac donor: a six-year experience. Ann Thorac Surg 1986;41:356-62.
30. Angstwurm H, Einhaupt K. Organ donors and brain death diagnosis: experiences in the diagnosis and documentation of brain death. Transplant Proc 1984;16:95-7.
31. Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. N Engl J Med 1994;330:816-9.
32. Beizer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation 1988;45:673-6.
33. D'Allessandro AM, Sollinger HW, Hoffmann RM, et al. Experience with Belzer UW cold storage solution in simultaneous pancreas-kidney transplantation. Transplant Proc 1990;22:532-4.
34. Blanche C, Valenza M, Czer LSC, et al. Orthotopic heart transplantation with bicaval and pulmonary venous anastomoses. Ann Thorac Surg 1994;58:1505-9.
35. Brooks RG, Remington JS. Transplant-related infections. In: Bennet JV, Brachman PS, editors. Hospital infections. 2nd ed. Boston: Little Brown & Co; 1986. p. 561-618.
36. Flint A, Frank TS. Cytomegalovirus detection in lung transplant biopsy samples by polymerase chain reaction. J Heart Lung Transplant 1994;13:38-42.
37. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med 1994;149:1601-7.
38. Hughes WT, Rivera GK, Shell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316:1627-32.
39. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990;12:S754-66.
40. Saliba F, Ephraim R, Mathieu D, et al. Risk factors for bacterial infection after liver transplantation. Transplant Proc 1994;26:266.
41. Imakita M, Tazelaar HD, Billingham ME. Heart allograft rejection under varying immunosuppressive protocols as evaluated by endomyocardial biopsy. J Heart Transplant 1986;5:279-85.
42. Tesi RJ, Elkhammas EA, Henry ML, et al. OKT3 for primary therapy of first rejection episode in kidney transplants. Transplantation 1993;55:1023-9.
43. Costanzo-Nordin MR, Grusk BB, Silver MA, et al. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation 1988;78(Suppl III):47-57.
44. European FK506 Multicentre Liver Study Group. Randomized trial comparing Tacrolimus (FK506) and Cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8.
45. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994;57:848-51.
46. Jordan MD, Shapiro R, Vivas CA, et al. FK506 rescue for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994;57:860-5.
47. Crisp SJ, Dunn MJ, Rose JS, Barber J, Yacoub MH. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease? J Heart Lung Transplant 1994;13:81-92.
48. Gao SZ, Schroeder JS, Alderman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Circulation 1989;80(Suppl III): 100-5.
49. Costanzo-Nordin MR, O'Sullivan J, Johnson MR, et al. Prospective randomized trial of OKT3 versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 1990;9:306-15.
50. Miller LW, Wolford T, McBride LR, et al. Successful withdrawal of corticosteroids in heart transplantation. J Heart Transplant 1992;11:431-4.
51. Renlund DG, O'Connell JB, Gilbert EM, et al. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Transplant 1987;6:71-8.
52. Kobashigawa JA, Stevenson LW, Brownfield ED, et al. Initial success of steroid weaning late after transplantation. J Heart Lung Transplant 1992;11:428-30.
53. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998;66:507-15.
54. Miller LW, Naftel DC, Bourge RC, Kirklin JK, Brozena SC, Jarcho J, and the Transplant Cardiologists Research Database Group. Infection following cardiac transplantation: a multi-institutional analysis. J Heart Lung Transplant 1992;11:92.
55. O'Connell JB, Bourge RC, Costanzo-Nordin MR, et al. Cardiac transplantation: recipient selection, donor procurement, and medical follow-up: a statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1992;86:1061-79.
56. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983;68:785-95.
57. Konstam MA. The role of revascularization: heart failure and coronary artery disease. In: Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction: clinical practice guideline. Rockville, Md: US Dept of Health and Human Services; June 1994. AHCPR Publication 94-0612.
58. Dreyfus GD, Duboc D, Blasco A, et al. Myocardial viability assessment in ischemic cardiomyopathy: benefits of coronary revascularization. Ann Thorac Surg 1994;57:1402-8.